Marksans Pharma Share News - Latest Updates, Live News & More

Latest news about Marksans Pharma

Marksans Pharma's UK Subsidiary Secures Marketing Approval for Cetirizine Oral Solution Nov 20, 2025

Marksans Pharma Limited's wholly-owned UK subsidiary, Relonchem Limited, has received marketing authorization from the UK MHRA for Cetirizine Dihydrochloride 1 mg/ml Oral Solution. This approval expands Marksans Pharma's product portfolio in the UK pharmaceutical market, particularly in the antihistamine segment. The oral solution formulation of Cetirizine, used to relieve allergy symptoms, may provide an alternative option for patients who prefer liquid medications or have difficulty swallowing tablets.

Marksans Pharma's UK Subsidiary Secures Regulatory Approval for Pain Relief Medication Nov 17, 2025

Marksans Pharma Unveils Ambitious Growth Strategy: $300M US Order Book and INR 5,000 Crore Revenue Target Nov 15, 2025

Marksans Pharma Reports Mixed Q2 Results: Revenue Up, Margins Under Pressure Nov 14, 2025

Marksans Pharma's Goa Facility Aces FDA Inspection with Zero Observations Nov 10, 2025

More news about Marksans Pharma

05Nov 25

Marksans Pharma's UK Subsidiary Secures Marketing Authorization for Exemestane Tablets

Marksans Pharma Limited's wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Exemestane 25mg film-coated tablets. This approval allows the company to market the product in the UK, potentially expanding its market presence and revenue opportunities in the region. Marksans Pharma, a Mumbai-based pharmaceutical company, specializes in generic pharmaceutical formulations and has a global presence with manufacturing facilities in India, USA, and UK.

15Oct 25

Marksans Pharma's UK Subsidiary Secures Approval for Clonidine Tablets

Marksans Pharma's wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two Clonidine tablet products. The approval covers Clonidine Tablets (100 microgram) and Clonidine Hydrochloride Tablets (25 microgram). This development allows Marksans Pharma to expand its product offerings in the UK pharmaceutical market, potentially boosting its growth in the European sector.

23Sept 25

Marksans Pharma's UK Arm Secures Approval for Moxonidine Tablets

Marksans Pharma's wholly-owned UK subsidiary, Relonchem Limited, has obtained Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Moxonidine 200 microgram and 400 microgram Tablets. Moxonidine is used to treat mild to moderate essential hypertension. This approval allows Relonchem to market these products in the UK, potentially expanding Marksans Pharma's presence in the cardiovascular therapeutic segment. The authorization aligns with the company's strategy to strengthen its global generic pharmaceutical portfolio.

05Sept 25

Marksans Pharma Reports Strong Financial Performance with 30% Revenue Growth and Recommends Rs 0.60 Final Dividend

Marksans Pharma announced robust financial results for FY 2024. Consolidated revenue increased by 17.6% to Rs 21,774.07 million, while profit grew 18.7% to Rs 3,148.95 million. The company's standalone performance was even stronger, with revenue up 30.2% and profit up 30%. The Board recommended a final dividend of Rs 0.60 per share. In April 2023, Marksans acquired a manufacturing facility in Goa for Rs 779.47 million, potentially boosting future growth.

19Aug 25

Marksans Pharma Reports 5% Revenue Growth Amid Mixed Regional Performance

Marksans Pharma reported a 5% YoY revenue growth to INR 620.00 crores in its latest quarter. U.S. market revenue increased by 30.6% to INR 327.60 crores, driven by new product launches. However, U.K. and EU formulations market saw a 20% decline to INR 203.80 crores due to seasonal factors and pricing pressures. Gross profit rose 8.9% YoY, but profit after tax decreased by 34.7%. The company launched new products in the U.K., received regulatory approvals, and is expanding capacity with a new facility in Goa. The U.S. order book stands at $220.00 million. Challenges include pricing pressures in the U.K. and potential U.S. tariffs on pharmaceutical imports.

18Aug 25

Marksans Pharma's UK Subsidiary Secures Marketing Authorization for Metformin Products

Marksans Pharma Limited's UK subsidiary, Relonchem Limited, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for three Metformin Hydrochloride prolonged-release tablet products (500 mg, 750 mg, and 1000 mg). This approval represents a significant milestone for Marksans Pharma's international operations and expansion in the UK pharmaceutical market, particularly in the treatment of type 2 diabetes.

14Aug 25

Marksans Pharma Adjusts FY26 Revenue Expectations, Maintains Strong US Order Book

Marksans Pharma expects to miss its Rs 3,000 crore revenue target for FY26. UK revenue is projected to remain flat, while the US market shows promise with a $220 million order book. The company anticipates margins between last year's levels and 17%. Recent achievements include 3 regulatory approvals and 4 high-margin product launches in the UK. Management declined to provide FY27 guidance.

12Aug 25

Marksans Pharma Reports Mixed Q1 Results: Revenue Up, Profits Down

Marksans Pharma's Q1 results show a 5% YoY revenue increase to ₹620.00 crore, driven by US market growth. However, net profit declined 34.7% to ₹58.20 crore, and EBITDA fell 22% to ₹100.10 crore. The US & North America segment grew 30.6%, while UK & Europe declined 19%. Managing Director Mark Saldanha attributed the profit margin impact to ramp-up costs, ECL provision, and forex adjustments, but expressed optimism about future growth prospects.

25Jul 25

Marksans Pharma Re-appoints Mark Saldanha as Managing Director for Five-Year Term

Marksans Pharma Limited has announced the re-appointment of Mark Saldanha as Managing Director for another five-year term, starting October 6, 2025, subject to shareholder approval. Saldanha, with over 24 years of industry experience, will receive an annual remuneration of Rs. 6,00,00,000.00, including a monthly basic salary of Rs. 40,00,000.00. The decision, recommended by the Nomination and Remuneration Committee, aligns with the company's corporate governance practices. Shareholders will vote on this at the 33rd Annual General Meeting on August 8, 2025.

30Jun 25

Marksans Pharma Receives FDA Clearance for Time-Cap Laboratories Facility

Marksans Pharma has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration for its Time-Cap Laboratories manufacturing facility. This signifies successful completion of the FDA inspection process and compliance with current good manufacturing practice requirements. The EIR is crucial for Marksans Pharma's regulatory standing in the U.S. market and could boost stakeholder confidence, potentially leading to expanded product offerings and market presence in the United States.

19Jun 25

Marksans Pharma's UK Unit Secures Approval for Bladder Medication

Marksans Pharma's UK subsidiary has received regulatory approval for Oxybutynin Hydrochloride Oral Solution, a medication used to treat bladder and urinary conditions. This approval allows the company to market and distribute the product in the United Kingdom, potentially strengthening its position in the UK pharmaceutical market and expanding its revenue opportunities.

30May 25

Marksans Pharma: UK Regulator Approves Subsidiary's Diabetes Medication

Relonchem Limited, a UK subsidiary of Marksans Pharma, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Metformin Hydrochloride 500 mg/5ml Oral Solution. This approval allows Relonchem to market and sell this formulation of the diabetes medication in the UK market, potentially strengthening Marksans Pharma's position in the anti-diabetic segment.

19May 25

Marksans Pharma Reports Q4 Growth: EBITDA and Net Profit Rise

Marksans Pharma's Q4 results show significant growth with revenue increasing 26.79% year-over-year to ₹7.10 billion. EBITDA rose to ₹1.26 billion, though EBITDA margin slightly decreased to 17.74%. Net profit grew 16.67% year-over-year to ₹0.91 billion, but showed a slight quarter-over-quarter decline. The company demonstrates robust growth despite some margin pressures, indicating resilience in a challenging market.

19May 25

Marksans Pharma's UK Subsidiary Secures Approval for Sennosides Tablets, Shares Surge

Marksans Pharma Limited's UK subsidiary, Relonchem Limited, has received marketing authorization from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for Sennosides 7.5 mg Tablets. The company also recently obtained approval for Gabapentin oral solution. These approvals are expected to strengthen Marksans Pharma's position in the UK pharmaceutical market. The company's shares gained over 6% following the announcement.

15May 25

Marksans Pharma's UK Subsidiary Secures Marketing Authorization for Gabapentin Oral Solution

Marksans Pharma Limited's UK subsidiary, Relonchem Ltd, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Gabapentin 50 mg/ml oral solution. This approval allows the company to market and sell the medication in the UK, potentially expanding its presence in the Central Nervous System (CNS) disorders treatment market. Gabapentin is used to treat conditions such as epilepsy, neuropathic pain, and certain anxiety disorders. The oral solution format may improve accessibility for patients who have difficulty swallowing tablets or capsules.

20Mar 25

Marksans Pharma Expands Global Reach: Goa Facility Approved by Australian TGA

Marksans Pharma Limited's manufacturing facility in Goa has received approval from the Australian Therapeutic Goods Administration (TGA) for producing pharmaceutical formulations for Australian markets. The approval covers solid dosage forms including tablets and hard capsules. This milestone enhances the company's global manufacturing footprint, which now includes facilities approved by USFDA, UKMHRA, and Australian TGA. The company plans to distribute products in Australia through its subsidiary, Nova Pharmaceuticals Australasia Pty Ltd. Additionally, Marksans Pharma's UK subsidiary recently received Marketing Authorization from UK MHRA for Baclofen 10 mg Tablets.

19Mar 25

Marksans Pharma's UK Arm Secures MHRA Approval for Baclofen Tablets

Marksans Pharma Limited's UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Baclofen 10mg tablets. Baclofen is used to treat muscle spasticity in conditions like multiple sclerosis and spinal cord injuries. This approval is expected to strengthen Marksans Pharma's position in the UK pharmaceutical market and contribute to its revenue growth.

25Feb 25

Marksans Pharma's UK Arm Secures Marketing Nod for Dual Action Pain Relief Tablets

Marksans Pharma's UK subsidiary, Relonchem Limited, has received marketing authorization for Ibuprofen and Paracetamol 200 mg/500 mg film-coated tablets in the UK. The product will be marketed as Bell's Healthcare Dual Action Pain Relief tablets. This approval aligns with Marksans' expansion strategy in the UK market, where the company aims to double its revenue within 5-7 years. Marksans reported strong Q3 FY2025 results with 16.3% YoY revenue growth to INR 682 crores, including 37.1% growth in the US market and 2.6% growth in the UK & EU. The company has 34 products awaiting approval in the UK and is targeting overall revenue of INR 3,000 crores in the near term.